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Objective. To analyse the potential risk factors of nosocomial infections in patients with active rheumatoid arthritis (RA).
Methods. A total of 2452 active RA patients at Hospitals in Shanghai between January 2009 and February 2011 were analyzed.
Their demographic and clinical characteristics were compared with those without infection, and the potential risk factors were
determined by logistic regression analysis. Results. Multivariate analysis indicated the gender (OR = 0.70, 95% CI 0.53–0.92),
duration in hospital (OR = 1.03 , 95%CI 1.01–1.05), number of organs involved (OR = 0.82, 95%CI 0.72–0.92), number of
disease-modifying antirheumatic drugs ((DMARDs) (OR = 1.22, 95%CI 1.061–1.40)), corticosteroid therapy (OR = 1.02, 95%CI
1.01–1.03), peripheral white blood cell counts ((WBC) (OR = 1.04, 95%CI 1.00–1.08)), levels of serum albumin (OR = 0.98,
95%CI 0.97–0.99), and C-reactive protein ((CRP) (OR = 1.03 , 95%CI 1.01–1.04)) that were signiﬁcantly associated with the
risk of infections. Conclusion. The female patients, longer hospital stay, more organs involved, more DMARDs, corticosteroid
usage, high counts of WBC, lower serum albumin, and higher serum CRP were independent risk factors of infections in active RA
patients.
1.Introduction
RA is a chronic inﬂammatory autoimmune disease with
unknown etiology and has an increased risk of infection
compared with the general population [1]. Previous stud-
ies have shown that microbial infection, particularly for
genitourinary and bronchopulmonary infection, contributes
to increased rate of mortality in RA patients [2, 3]. It2 ISRN Rheumatology
has been a serious concern that RA patients acquire mi-
crobial infection during hospitalization. Notably, about 5–
10% of RA patients may acquire a microbial infection
after their admission, and the hospital-related infection
rate in RA patients has been increasing in the USA and
other countries during the past decades [4]. Those patients
acquire infection with the common hospital-related drug-
resistant pathogens, including methicillin-resistant Staphy-
lococcus aureus (MRSA), antibiotic-resistant Gram-negative
bacilli and, more recently, vancomycin-resistant enterococci
[5]. More importantly, these nosocomial infections are
diﬃculttocontrol,leadingtoahighmortality,particularlyin
individuals with immunodisorder. Therefore, understanding
potential risk factors associated with the high susceptibility
will be of great signiﬁcance in the prevention and control of
nosocomial infection.
RA patients have unbalanced immunoregulation and
often receive corticosteroids and other immunomodulatory
therapies, which can deteriorate their immune responses,
increasing their susceptibility to microbial infection. Fur-
thermore, the incidence of RA in China is increasing and
many patients with acute RA require hospitalization, which
increases their opportunity for nosocomial infection. There
are many tertiary hospitals providing services for people in
Shanghai, the biggest city in China. However, there is no
systemic investigation on the risk factors associated with the
susceptibility of RA patients to nosocomial infection.
In this study, we aimed at analyzing the potential risk
factors associated with nosocomial infection in patients with
active RA (Figure 1).
2.SubjectsandMethods
We analyzed the medical charts of 2452 patients who had
been diagnosed with RA, according to the criteria of the
American College of Rheumatology [6] at hospitals in
Shanghai between January 2009 and February 2011. Indi-
vidual patients were included if they had RA for more than
three months with a disease activity score >3.2, based on
erythrocytesedimentationrateandanevaluationof28joints
(DAS28) [7]. Individuals with other diseases were excluded.
Written informed consent was obtained from individual
patients, and the experimental protocol was approved by the
Ethics Committee of the Second Military Medical University
of Medicine, Shanghai, China.
Those patients with a history of nosocomial infection
at 48h or later after admission, according to the criteria of
CDC deﬁnitions for nosocomial infections [8], were counted
as patients with infection, while other patients who had no
relevant infectious episode throughout the hospitalization
were in the noninfection group. The criteria for an infectious
episode were documentations of the microorganism and/or
clinicalﬁndingsincombinationwitheitherradiographicand
endoscopicdiagnosisorresponsetoantibiotics.Opportunis-
tic organisms were designated, according to Cohen’s lists
based on the principles proposed by von Graevenitz [9]. The
type, site, and outcome of all nosocomial infections were
recorded for each case.
Subjects meeting
inclusion criteria
(n = 2788)
Immunity acquired infection
(eclipse period ≤48 hours)
(n = 336)
Study cohort
(n = 2452)
Infection group
(n = 553)
No infection group
(n = 1899)
Figure 1: Flow diagram of study on RA patients at hospitals in
Shanghai.
Data are expressed as the real case, %, or mean ±SD of
each group of patients. Categorical variables were analyzed
using the χ2 test and Fisher’s exact test, where appropriate.
Continuous variables were analyzed using Student’s t-test.
A 2-tail P value of 0.05 was considered to be statistically
signiﬁcant. The demographic and clinical characteristics of
patients were taken into account as the potential risk factors,
and they included age, gender, the duration of diseases,
number of comorbidities, the duration of hospitalization,
number of organs involved, number of disease modifying
antirheumatic drugs (DMARDs), corticosteroid therapy,
pulse cyclophosphamide therapy, Etanercept therapy, the
peripheral white blood cell counts (WBCs), platelet, and
eosinophils counts, the concentrations of serum globin,
hemoglobin, serum albumin, C-reactive protein (CRP), ery-
throcyte sedimentation rate (ESR), immunoglobulin (Ig) G,
IgA, and IgM. We ﬁrst determined the potential risk factors
associated with infection using a univariate analysis and
furtheranalyzedtheassociationofthesepotentialriskfactors
identiﬁed with infection in this population by a multivariate
analysis using stepwise logistic regression. The statistical
signiﬁcance of risk factors associated with infection was
assessed by means of 95% conﬁdence intervals.
3. Results
The predisposition of female patients, the duration in hos-
pital, the number of organs aﬀected and DMARDs, the
dosage of corticosteroids, the frequency of cases with pulse
cyclophosphamide, the blood WBC and eosinophil counts,
the concentrations of HB, ALB, CRP, and ESR in the patients
with nosocomial infection were signiﬁcantly greater thanISRN Rheumatology 3
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that in noninfection patients, determined by univariate anal-
ysis (Table 1). However, there was no signiﬁcant diﬀerence
in the mean age, the duration of the disease, the number of
comorbidities,Etanercepttherapy,andthelevelofbloodPLT
counts, globin, IgG, IgA, and IgM between the RA patients
with noninfection and with infection. A multivariate logistic
regression analysis revealed that the predisposition of female
patients, the duration in the hospital, the number of organs
aﬀected, the number of DMARDs, corticosteroid therapy,
blood WBC counts, and the concentrations of blood ALB
and CRP were signiﬁcantly independently associated with
increased risk for infection in this population.
4. Discussion
A previous study has shown that RA patients have a nearly 2-
fold increased risk for infection, compared with that of age-
andsex-matchedcontrolsubjects[10].Theincreasedriskfor
infections may be due to intrinsic and extrinsic defects. First,
many RA patients show an accelerated immunosenescence,
particularly in T cells [11]. These abnormalities may explain
the high susceptibility of RA patients to nosocomial infec-
tion before treatment with immunosuppressive therapeutics.
Second, aging, pulmonary disease, and diabetes mellitus
are independent risk factors for bacterial infection in RA
patients [12]. In our study, we found that female patients,
longer duration in hospital, more organs aﬀected by RA,
more number of DMARDs, with corticosteroid therapy, and
higher blood WBC counts, the higher levels of ALB and
CRP were associated signiﬁcantly with increased risk for the
development of nosocomial infection. Indeed, male patients
have less risk for nosocomial infection than women (OR =
0.70, 95%CI 0.53–0.92), and individual patients hospitalized
for more than 12.31 (SD, 6.32) days have an increased
risk for nosocomial infection (OR = 1.03, 95%CI 1.01–
1.05). Furthermore, patients with less organs aﬀected by RA
were at a decreased risk for nosocomial infection (OR =
0.82, 95%CI 0.72–0.92). Moreover, we found that the RA
patients with infection were signiﬁcantly associated with
the use of DMARD (OR = 1.22, 95%CI 1.061–1.40) and
the dose of corticosteroids (OR = 1.02, 95%CI 1.01–1.03),
which are consistent with these observations [13, 14], but
in disagreement with another study [15]. D´ ıaz-Lagares et al.
observed an increased risk for infection in hospitalized RA
patients, which was only associated with a slightly increased
risk for the Etanercept therapies (HR 1.54, 95% CI 1.20–
1.97) [16]. However, we observed no association of the
Etanercept therapy with the increased risk for infection in
RA patients. We also observed that serum hypoalbumin (OR
= 0.98, 95%CI 0.97–0.99), high counts of WBC (especially,
neutrophils, OR = 1.04, 95%CI 1.00–1.08), and high levels of
serum CRP (OR = 1.03, 95%CI 1.01–1.04) were associated
with increased risk for infection in RA patients. Hence,
the abnormal levels of these measures may be used for the
evaluation of infection in RA patients.
All previous reports of infection are studied in RA
patients in out-patient clinic (OPD), secondary, tertiary re-
ferral centers, or community. These studies may not provide
a reliable estimation of the frequency of infection in RA
patients. In the present study, we analyzed risk factors in
hospitalized RA patients. This should allow us to predict the
infection with other rheumatic disease patients.
We recognized that the present study had limitations.
First, we conducted this observational study, based on a
observational chart review data so that these ﬁndings could
still be aﬀected by unmeasured or unknown confounders,
although we adjusted for all known risk factors for infection
available in our administrative data. Furthermore, the analy-
sis did not control for some disease characteristics at baseline
speciﬁcally. We described disease activity or severity and
the exposure to DMARDs as the number of organs aﬀected
and number of DMARDs, respectively. Finally, because the
majority of residents in Shanghai are Chinese Han, our
ﬁndings may be not generalized to the whole Chinese pop-
ulation.
5. Conclusion
Our results indicated female patients, longer duration in
hospital, more organs aﬀected by RA, more DMARDs and
corticosteroid therapy, high counts of WBC, and lower
concentrations of blood ALB, and higher levels of serum
CRP were signiﬁcantly and independently associated with
increased risk for infection in RA patients. Apparently,
these abnormal measures may be used for the diagnosis
of infection in active RA patients. Given that infection is
a serious challenge for the management of RA patients,
it is important to identify infection and determine the
susceptibility of pathogens to antibiotics for the control of
infection in RA patients. Of course, further longitudinal
prospective studies with diverse and big populations to
conﬁrm our ﬁndings are warranted in order to monitor and
to prevent nosocomial infection in RA patients in China.
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